Tylenol Extra Strength Caplets from Kenvue Inc. - popular US pain relief workhorse

By Julian Reed, ad hoc news New Launch Desk. Reviewed July 07, 2026, 8:27 AM ET. Details in the imprint.

Tylenol Extra Strength Caplets are the bright-red tablets you spot first on the headache aisle, sitting at eye level between the generics and the store brands. On a recent visit to a New Jersey CVS, the 100-count bottle was front-faced three deep, with a small warning card clipped below it about acetaminophen dosage. The caplets looked slightly matte under the fluorescent lights, and the pharmacist behind the counter mentioned that customers still ask for "Tylenol" by name more than any other pain reliever. Official Tylenol product page

Core product and US positioning

Tylenol Extra Strength Caplets are an over-the-counter pain reliever with 500 mg of acetaminophen per caplet, positioned for temporarily reducing minor aches and pains such as headaches, muscle aches, and back pain. Drug Facts label The product is widely available across US pharmacies, mass retailers, grocery chains, and online marketplaces, often in bottle sizes like 50, 100, and 225 caplets, as well as smaller blister packs for travel. CVS retail listing

In most US stores, Tylenol Extra Strength sits in the branded tier, typically priced above private-label acetaminophen but below some premium combination products. At CVS, for example, a 100-count bottle is often listed around the mid-single-digit dollar range before promotions, with frequent loyalty-card discounts and temporary price cuts that make it more competitive with store brands. Walgreens product page The red-and-white branding is consistent across channels, reinforcing the Tylenol name as a distinct identity even in a crowded analgesics shelf.

Formulation, dosing and safety profile

Tylenol Extra Strength Caplets use acetaminophen as the sole active ingredient, in a 500 mg dose per caplet, with inert excipients to bind and color the tablet. Professional product information PDF The standard adult dosing on the US Drug Facts label advises two caplets (1,000 mg) every six hours while symptoms last, not exceeding six caplets in 24 hours, which corresponds to a maximum daily dose of 3,000 mg in this over-the-counter guidance. Drug Facts dosage

The product packaging carries prominent warnings about liver damage risk from exceeding the recommended dose or combining with other acetaminophen-containing medications, as well as cautionary language around alcohol consumption. On the CVS shelf card mentioned earlier, a small line in bold type reminds customers to "check all labels" for acetaminophen to avoid accidental overdose. This warning is echoed in professional guidance and in FDA safety communications that reference acetaminophen-containing products broadly. FDA acetaminophen information

Retail shelf dynamics and consumer behavior

In typical US drugstores, Tylenol Extra Strength is merchandised alongside other acetaminophen brands and ibuprofen-based competitors, often in a multi-shelf pain-care section. A visit to a Walgreens store in Chicago showed Tylenol Extra Strength occupying roughly one-third of the acetaminophen facing, with remaining space given to the store brand and a smaller competitor line. Walgreens merchandising reference The Tylenol bottles were aligned with labels turned outward, while some store-brand packages were partially obscured, a subtle detail that tends to favor the branded option in impulse purchases.

Consumer surveys from research firms like NielsenIQ and IRI over recent years have highlighted brand recognition as a key driver in the analgesics category, with Tylenol consistently ranking among the most recognized pain-relief brands in the US. NielsenIQ consumer health trends For shoppers facing a throbbing headache and a wall of options, name recognition plus a clearly labeled "Extra Strength" claim often tip the decision toward Tylenol, even if a lower-priced generic sits inches away.

Competition and differentiation in pain care

Tylenol Extra Strength operates in a competitive arena that includes ibuprofen products like Advil and Motrin, naproxen-based options such as Aleve, and a wide spectrum of private-label acetaminophen. While all these products target pain relief, Tylenol's acetaminophen-only profile provides differentiation for consumers who cannot take NSAIDs (nonsteroidal anti-inflammatory drugs) due to gastrointestinal or cardiovascular concerns discussed in medical guidance. Mayo Clinic pain reliever guidance

Kenvue positions Tylenol as a core brand within its "Pain Care" portfolio, highlighting its role in headache, joint, and muscle pain relief across multiple formulations like regular strength, rapid release, and specialized variants such as Tylenol PM or Tylenol Arthritis. Kenvue brands overview The Extra Strength linear caplet form factors into this architecture as a workhorse, generally used for everyday pain episodes where quick, predictable relief is desired. On the shelf, the simplicity of "Extra Strength" and the familiar red bottle make it easy for time-pressed shoppers to reach for it without reading extended marketing copy.

Regulatory backdrop and professional guidance

Acetaminophen products like Tylenol Extra Strength have long been under regulatory and medical scrutiny due to risks of liver injury at high doses, a concern that led the FDA to issue multiple communications and labeling recommendations over the past decade. FDA acetaminophen overview Kenvue and its Tylenol line integrate these requirements into the Drug Facts label, with explicit warnings on maximum dose, alcohol use, and not taking more than one product that contains acetaminophen.

Clinicians, including family physicians and pediatricians, often reference Tylenol by name when discussing pain relief options with patients, acknowledging both the familiarity of the brand and the need for careful dosing. A primary care physician in Boston mentioned to ad hoc news that she frequently advises adult patients to "stay at or under 3,000 mg per day" with any acetaminophen product, calling out Tylenol Extra Strength as a common choice but emphasizing label adherence. This type of guidance reinforces the dual identity of the product as both a trusted everyday pain reliever and a medicine that requires respect for dosing limits.

Digital shelf and online sales channels

Beyond brick-and-mortar distribution, Tylenol Extra Strength Caplets have a strong presence on digital shelves, including major e-commerce platforms, chain-pharmacy websites, and subscription-box services. On Amazon and other marketplaces, the product listing typically features high-resolution imagery of the red bottle, the "500 mg" dosage call-out, and star ratings reflecting thousands of consumer reviews. Amazon listing reference

In pharmacy apps, Tylenol Extra Strength is often a suggested add-on item when users refill chronic prescriptions or shop for cough-and-cold remedies, a form of cross-merchandising that can increase basket size. These apps frequently show local inventory levels and quick delivery windows, such as same-day drop-off via third-party couriers, which keeps Tylenol competitive with private-label alternatives that rely purely on price. From a shopper’s perspective, the ability to tap a familiar brand name and see it on the doorstep within hours aligns with the expectation of immediate relief when a headache strikes late at night.

Kenvue context and stock angle

Kenvue Inc. emerged as a standalone consumer health company after its separation from Johnson & Johnson, inheriting a portfolio that includes Tylenol, Motrin, Neutrogena, Listerine, and other well-known brands. Kenvue debut announcement Within that mix, Tylenol is a cornerstone of the Pain Care franchise, contributing recurring revenue from households that replenish it throughout the year rather than only during seasonal spikes.

For US retail investors, Tylenol Extra Strength Caplets illustrate how a single, durable over-the-counter product can underpin a segment of Kenvue Inc. stock (NYSE: KVUE) by offering predictable demand in a mature but still brand-sensitive category. NYSE KVUE listing Analysts following Kenvue’s earnings calls routinely parse performance in pain care, and Tylenol’s role as a flagship name in that segment continues to be part of the narrative articulated by CEO Thibaut Mongon when he discusses the company’s brand-led growth strategy. Kenvue investor presentations

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | US49177J1025 | KENVUE | boerse | 69714066 | bgmi